IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Co.'s clinical and preclinical product candidates are: INB-200, which is a genetically modified autologous gamma-delta T cell product in a Phase 1 clinical trial; INB-100, which is Co.'s allogeneic DeltEx product candidate that is being administered in a dose-escalation Phase 1 clinical trial for the treatment of patients with hematologic malignancies; and INB-400, which is in a Phase 2 clinical trial using Co.'s autologous DeltEx drug resistant immunotherapy product candidate to treat newly diagnosed glioblastoma. The INAB average annual return since 2021 is shown above.
The Average Annual Return on the INAB average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INAB average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INAB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|